During an investor conference yesterday, Lotus Pharmaceutical Vice President Ben Shen outlined an ambitious growth trajectory for 2026. Despite a projected 50% decline in revenue from its blockbuster leukemia drug Lenalidomide due to patent expiry and price erosion, the company aims for annual revenue of US$1.1–1.2 billion.

Strategic Growth Pillars:

• Alvogen Consolidation: Full-year revenue contribution from the Alvogen acquisition will provide a massive structural floor for the group's finances.
• Q2 Launch Pipeline: Three major products—a functional GI disorder treatment, a respiratory delivery device, and a branded mood stabilizer—are slated for launch starting in the second quarter to offset generic competition.
• Asian Momentum: Following a 91% YoY surge in Southeast Asian revenue last year, Lotus continues to see strong growth in Thailand and through the acquisition of Alpha Choay.
• Dividend Policy: Addressing a lower-than-expected dividend of NT$2.69, Shen explained that the company is prioritizing debt repayment to reduce interest expenses following large-scale M&A. He urged shareholders to remain patient as the company optimizes its financial structure to support even higher future payouts.

Resource: 美時Alvogen併購＋新品上市抵血癌藥下滑，今年營收拚增65%-80%